Hong Kong (HSI) Pharma Industry Analysis

Industry Valuation and Performance

Has the Hong Kong Pharma Industry valuation changed over the past few years?

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Thu, 21 May 2026	HK$682.8b	HK$519.8b	HK$29.7b	14.3x	23x	1.3x
Sat, 18 Apr 2026	HK$796.0b	HK$517.2b	HK$30.2b	15.3x	26.3x	1.5x
Mon, 16 Mar 2026	HK$734.3b	HK$498.8b	HK$30.4b	12.4x	24.1x	1.5x
Wed, 11 Feb 2026	HK$842.1b	HK$497.2b	HK$30.5b	13.4x	27.6x	1.7x
Fri, 09 Jan 2026	HK$834.5b	HK$490.9b	HK$30.1b	13.4x	27.7x	1.7x
Sun, 07 Dec 2025	HK$829.5b	HK$484.6b	HK$29.7b	13.7x	27.9x	1.7x
Tue, 04 Nov 2025	HK$799.3b	HK$480.4b	HK$30.1b	14x	26.6x	1.7x
Thu, 02 Oct 2025	HK$788.9b	HK$479.7b	HK$30.6b	13.1x	25.8x	1.6x
Sat, 30 Aug 2025	HK$793.1b	HK$480.1b	HK$30.8b	13.5x	25.7x	1.7x
Mon, 28 Jul 2025	HK$723.6b	HK$476.0b	HK$29.1b	12.1x	24.9x	1.5x
Wed, 25 Jun 2025	HK$642.5b	HK$477.2b	HK$28.9b	11.9x	22.3x	1.3x
Fri, 23 May 2025	HK$551.5b	HK$475.9b	HK$29.1b	10.8x	19x	1.2x
Sun, 20 Apr 2025	HK$473.0b	HK$466.5b	HK$28.6b	10.2x	16.5x	1x
Tue, 18 Mar 2025	HK$463.3b	HK$465.4b	HK$32.0b	8.9x	14.5x	1x
Thu, 13 Feb 2025	HK$417.9b	HK$460.7b	HK$31.8b	8.7x	13.1x	0.9x
Sat, 11 Jan 2025	HK$400.2b	HK$459.2b	HK$31.7b	8.1x	12.6x	0.9x
Mon, 09 Dec 2024	HK$443.5b	HK$462.5b	HK$31.9b	8.3x	13.9x	1x
Wed, 06 Nov 2024	HK$452.4b	HK$472.2b	HK$32.7b	8.4x	13.8x	1x
Fri, 04 Oct 2024	HK$506.2b	HK$476.3b	HK$33.1b	7.8x	15.3x	1.1x
Sun, 01 Sep 2024	HK$444.0b	HK$474.5b	HK$32.9b	7.8x	13.5x	0.9x
Tue, 30 Jul 2024	HK$419.7b	HK$458.6b	HK$32.5b	7.5x	12.9x	0.9x
Thu, 27 Jun 2024	HK$446.0b	HK$461.9b	HK$33.8b	7.9x	13.2x	1x
Sat, 25 May 2024	HK$459.0b	HK$463.0b	HK$33.7b	8.5x	13.6x	1x
Mon, 22 Apr 2024	HK$423.1b	HK$464.6b	HK$33.8b	7.5x	12.5x	0.9x
Wed, 20 Mar 2024	HK$458.9b	HK$470.2b	HK$33.3b	7.6x	13.8x	1x
Fri, 16 Feb 2024	HK$415.4b	HK$472.6b	HK$33.8b	6.6x	12.3x	0.9x
Sun, 14 Jan 2024	HK$456.0b	HK$472.1b	HK$33.7b	7.6x	13.5x	1x
Tue, 12 Dec 2023	HK$469.3b	HK$471.4b	HK$33.6b	7.5x	14x	1x
Thu, 09 Nov 2023	HK$500.6b	HK$469.6b	HK$31.9b	7.1x	15.7x	1.1x
Sat, 07 Oct 2023	HK$424.5b	HK$469.6b	HK$31.6b	6.7x	13.4x	0.9x
Mon, 04 Sep 2023	HK$428.9b	HK$470.9b	HK$31.5b	6.9x	13.6x	0.9x
Wed, 02 Aug 2023	HK$486.8b	HK$446.5b	HK$27.9b	9.1x	17.5x	1.1x
Fri, 30 Jun 2023	HK$486.5b	HK$445.8b	HK$27.7b	9.7x	17.5x	1.1x
Sun, 28 May 2023	HK$519.2b	HK$449.7b	HK$28.0b	8.6x	18.5x	1.2x

Current Industry PE

Investors are optimistic on the Hong Kong Pharmaceuticals industry, and appear confident in long term growth rates.

The industry is trading at a PE ratio of 23.3x which is higher than its 3-year average PE of 18.1x.

The 3-year average PS ratio of 1.2x is lower than the industry's current PS ratio of 1.3x.

Past Earnings Growth

The earnings for companies in the Pharmaceuticals industry have remained mostly flat over the last three years.
Meanwhile revenues for these companies have grown 5.0% per year.
This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased and as a result, profits have held steady.

Industry Trends

Which industries have driven the changes within the Hong Kong Healthcare industry?


HK Market	-2.80%
Healthcare	-6.13%
Pharma	-6.56%
Pharma	-6.56%

Industry PEThere are no additional sub-industries under this industry.

Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

Company	Last Price	7D	1Y	Valuation
2637 Fujian Haixi Pharmaceuticals	HK$245.80	3.9% +HK$724.1m	n/a	PE95x
2348 Dawnrays Pharmaceutical (Holdings)	HK$1.13	0.9% +HK$15.0m	-5.0%	PE6.9x
1011 China NT Pharma Group	HK$0.61	1.7% +HK$9.5m	38.6%	PS20.8x
455 Tianda Pharmaceuticals	HK$0.091	3.4% +HK$6.5m	-36.8%	PS0.6x
858 Extrawell Pharmaceutical Holdings	HK$0.073	2.8% +HK$5.8m	40.4%	PS4x

Company

Last Price

Valuation

2637 Fujian Haixi Pharmaceuticals

HK$245.80

3.9%
+HK$724.1m

n/a

PE95x

2348 Dawnrays Pharmaceutical (Holdings)

HK$1.13

0.9%
+HK$15.0m

-5.0%

PE6.9x

1011 China NT Pharma Group

HK$0.61

1.7%
+HK$9.5m

38.6%

PS20.8x

455 Tianda Pharmaceuticals

HK$0.091

3.4%
+HK$6.5m

-36.8%

PS0.6x

858 Extrawell Pharmaceutical Holdings

HK$0.073

2.8%
+HK$5.8m

40.4%

PS4x

Lanexa Biologics LLC Announces FDA Approval of LANGLARA an Interchangeable Biosimilar of Lantus

Lannett Company, Inc., Lanexa Biologics, a wholly owned subsidiary of Lannett, and Sunshine Lake Pharma announced that the U.S. Food and Drug Administration (FDA) has approved LANGLARA (insulin glargine-aldy), as a biosimilar to Lantus (insulin glargine), for the treatment of adults and pediatric patients with type 1 diabetes mellitus and adults with type 2 diabetes mellitus. The FDA has determined that LANGLARA is interchangeable with the reference drug, enabling pharmacists to substitute LANGLARA for Lantus without prescriber intervention in states that permit such substitution. The approval for LANGLARA was based on a comprehensive analytical, preclinical and clinical program which confirmed the PK/PD, efficacy, safety profile and immunogenicity of LANGLARA as compared to Lantus in patients with type 1 and type 2 diabetes. LANGLARA is manufactured by Sunshine Lake Pharma Co., Ltd., which is the pharmaceutical business arm of HEC Group and commercialized in the United States exclusively through Lanexa Biologics LLC, a newly formed wholly owned subsidiary of Lannett Company. FDA Biosimilar Interchangeability Designation: An interchangeable biosimilar is a biosimilar that may be substituted for the reference product without the intervention of the prescribing health care provider, depending on state pharmacy laws. Not all biosimilars are interchangeable biosimilars. A manufacturer must specifically seek FDA approval for an interchangeable product. The approval process for interchangeable biosimilars has additional requirements related to the potential for substitution. Patients receiving their medications through their pharmacies may be able to switch between a brand-name biological product and an interchangeable biosimilar. LANGLARA is manufactured by Sunshine Lake Pharma, a biopharmaceutical company with biologics manufacturing capabilities and a track record of regulatory compliance across international markets. The collaboration between Lannett and Sunshine Lake Pharma reflects a commitment to delivering high-quality, affordable biologic medicines to patients who need them. Sunshine Lake Pharma’s manufacturing facility has been designed and operated to meet the standards of both the FDA and international regulatory authorities, providing a robust and scalable supply chain for LANGLARA and future pipeline products. Lannett and Sunshine Lake Pharma also continue to collaborate on a short acting insulin aspart which is in development. Lanexa Biologics LLC is a wholly owned subsidiary of Lannett Company, Inc., established to serve as the commercial platform for Lannett’s biosimilar portfolio in the United States. Lanexa combines the distribution infrastructure, payer relationships, and regulatory expertise of its parent company with a dedicated focus on the unique commercial demands of the biologics market. The formation of Lanexa reflects Lannett’s commitment to biosimilars as a core growth driver and its belief that purpose-built commercial capabilities are essential to competing effectively in this space. LANGLARA is Lanexa’s inaugural insulin product. A short acting insulin aspart is also under development.

Hong Kong (HSI) Pharma Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

Upcoming dividend of HK$0.048 per share

CSPC Pharmaceutical Group Limited to Report Q1, 2026 Results on May 27, 2026

Sino Biopharmaceutical Signs Exclusive Deal With GSK to Bring New Hepatitis B Drug to China

United Laboratories Approved to Begin Trials of Once-Weekly Insulin Candidate in China

Simcere Pharmaceutical Group's (HKG:2096) Solid Profits Have Weak Fundamentals

Executive Director exercised options and sold HK$16m worth of stock

Lanexa Biologics LLC Announces FDA Approval of LANGLARA an Interchangeable Biosimilar of Lantus

New minor risk - Dividend sustainability

China NT Pharma Group Company Limited, Annual General Meeting, Jun 04, 2026

Tianda Pharmaceuticals Limited, Annual General Meeting, Jun 12, 2026

Investor sentiment deteriorates as stock falls 17%

Kontafarma China Holdings Limited, Annual General Meeting, Jun 05, 2026

New minor risk - Shareholder dilution

Investor sentiment improves as stock rises 17%